PD-1 monoclonal antibody

DRUG20 trials

Sponsors

Peking University, Guangzhou University of Traditional Chinese Medicine, Mabwell (Shanghai) Bioscience Co., Ltd., Sun Yat-sen University, The First Affiliated Hospital of Soochow University

Conditions

Advanced Solid TumorAngioimmunoblastic T-cell LymphomaColorectal CancerEBV InfectionEsophageal CancerExtensive-stage Small-cell Lung CancerGastric CancerGastroEsophageal Cancer

Early Phase 1

Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial of Hepatocellular Carcinoma Resistant to PD-1 Monoclonal Antibody

Not yet recruitingNCT06364800

Beijing 302 HospitalHepatocellular Carcinoma

Start: 2024-04-26End: 2026-09-26Target: 18Updated: 2024-04-15

Phase 1

Chimeric Antigen Receptor T Cells Targeting claudin18.2 in Solid Tumors.

CompletedNCT03874897

Peking UniversityAdvanced Solid Tumor

Start: 2019-03-26End: 2024-01-26Updated: 2024-04-30

Safety, Tolerability, and Pharmacokinetics of MW11 in Patients With Advanced Solid Tumors

Mabwell (Shanghai) Bioscience Co., Ltd.Advanced Solid Tumor

Start: 2020-09-03End: 2023-02-02Target: 21Updated: 2020-11-13

Ablation Combined With PD-1 in HCC: Phase II Study

Sun Yat-sen UniversityHepatocellular Carcinoma

Start: 2020-12-15End: 2024-06-30Target: 30Updated: 2023-04-19

Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial for First-line Treatment of Hepatocellular Carcinoma

Not yet recruitingNCT06364787

Beijing 302 HospitalHepatocellular Carcinoma

Start: 2024-04-26End: 2026-09-26Target: 18Updated: 2024-04-15

Phase 2

A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Colorectal Cancer and Other Gastrointestinal Tumors

RecruitingNCT06008054

Sichuan Baili Pharmaceutical Co., Ltd.Colorectal Cancer, Esophageal Cancer, Gastric Cancer

Start: 2023-11-16End: 2027-12-31Target: 376Updated: 2025-09-26

A Study of BL-M07D1 Combination Therapy in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma

RecruitingNCT06423885

Sichuan Baili Pharmaceutical Co., Ltd.HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma

Start: 2024-12-24End: 2026-10-31Target: 40Updated: 2025-08-06

A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors

RecruitingNCT06437522

Sichuan Baili Pharmaceutical Co., Ltd.Head and Neck Squamous Cell Carcinoma

Start: 2024-06-07End: 2026-06-30Target: 46Updated: 2025-05-07

A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer

RecruitingNCT06437509

Sichuan Baili Pharmaceutical Co., Ltd.Extensive-stage Small-cell Lung Cancer

Start: 2024-06-13End: 2026-06-30Target: 66Updated: 2025-05-07

Synergistic Effects of PD-1 Antibody and Chemotherapy/Targeted Therapy Followed by Surgery-centric Local Treatment in Patients With Limited-metastatic Gastric Cancer

RecruitingNCT06468280

Shanghai Zhongshan HospitalGastric Cancer, GastroEsophageal Cancer

Start: 2024-11-08End: 2028-12-01Target: 84Updated: 2026-01-21

A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer

RecruitingNCT06471205

Sichuan Baili Pharmaceutical Co., Ltd.Triple-negative Breast Cancer

Start: 2024-08-02End: 2026-07-31Target: 52Updated: 2025-05-07

A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors

RecruitingNCT06475300

Sichuan Baili Pharmaceutical Co., Ltd.Nasopharyngeal Carcinoma, Non-small Cell Lung Cancer, Solid Tumor

Start: 2024-06-25End: 2026-07-01Target: 570Updated: 2026-01-21

Neoadjuvant Long-course Chemoradiotherapy Followed by Immunotherapy for Locally Advanced Mid-low Rectal Cancer

CompletedNCT06493240

Peking University People's HospitalLocally Advanced Rectal Cancer

Start: 2023-01-01End: 2025-04-01Updated: 2025-11-25

SCRT + mFOLFOX6 + PD-1 Antibody + Targeted Therapy for HIgh-Risk pMMR/MSS Rectal Cancer

RecruitingNCT06908031

Sixth Affiliated Hospital, Sun Yat-sen UniversityHigh-Risk Cancer, MSS, Rectal Adenocarcinoma

Start: 2025-04-02End: 2027-04-01Target: 49Updated: 2025-05-14

A Phase II Trial Comparing Immunotherapy Versus Capecitabine Maintenance After Chemo-chemoradiotherapy for High-risk Nasopharyngeal Carcinoma

RecruitingNCT07392320

Sun Yat-sen UniversityNasopharangeal Cancer

Start: 2026-02-04End: 2033-02-04Target: 142Updated: 2026-02-06

Phase 3

SBRT + PD-1 Monoclonal Antibody in Unresectable Colorectal Liver Metastases

RecruitingNCT06794086

Jun HuangColorectal Cancer, Liver Metastases

Start: 2025-04-10End: 2027-01-20Target: 24Updated: 2025-05-13

Phase 4

Programmed Cell Death Protein-1 (PD-1) Monoclonal Antibody for EBV-HLH and CAEBV as First-line Therapy

The First Affiliated Hospital of Soochow UniversityEBV Infection

Start: 2021-05-15End: 2023-04-30Target: 36Updated: 2021-09-09

Precision Adjuvant Therapy After Surgery for Hepatocellular Carcinoma

RecruitingNCT06311929

Chen XiaopingHCC

Start: 2024-04-01End: 2028-12-31Target: 300Updated: 2024-05-07

Unknown Phase

PD-1 Monoclonal Antibody in Pre-treated Lymphoepithelioma-like Carcinoma

Guangzhou University of Traditional Chinese MedicineLymphoepithelioma-Like Carcinoma

Start: 2020-06-01End: 2022-10-01Target: 12Updated: 2020-06-12

Chemotherapy Plus PD-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T-cell Lymphoma.

Ou Bai, MD/PHDAngioimmunoblastic T-cell Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified

Start: 2023-03-23End: 2024-12-31Target: 34Updated: 2023-04-20

Related Papers

Impact of concomitant medications on efficacy of CLDN18.2-specific CAR-T cell therapy in advanced gastric cancer.

2025-11-29

Synergistic effects of PD-1 antibody and chemotherapy followed by surgery-centric local treatment in patients with limited-metastatic gastric or gastroesophageal adenocarcinoma (ROSETTE trial): an open-label, single-center, randomized phase 2 trial

BMC Cancer2025-06-01

Stereotactic body radiotherapy combined with PD-1 antibody in unresectable colorectal liver metastases: A prospective, multicenter, single-arm, phase II study (SPARKLE-L).

Journal of Clinical Oncology2025-05-281 citations

Decoding the response and resistant features to the Claudin18.2-specific CAR-T cell CT041 in gastric cancer: A multi-omics exploratory biomarker analysis of the phase 1 clinical trial.

Journal of Clinical Oncology2025-05-281 citations

Peripheral blood neutrophils contribute to Claudin18.2-specific CAR-T cell treatment resistance in advanced gastric cancer.

2025-04-171 citations

Exploring the therapeutic efficacy difference in claudin18.2-targeted cell therapy revealed by single-cell sequencing

iScience2025-01-074 citations

Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results.

2024-06-03112 citations

Claudin18.2-targeted chimeric antigen receptor T cell-therapy for patients with gastrointestinal cancers: Final results of CT041-CG4006 phase 1 trial.

Journal of Clinical Oncology2024-06-019 citations

Abstract 6316: Exploring the resistant mechanism of CAR T cell therapy targeting CLDN18.2 by single-cell sequencing

Cancer Research2024-03-22

CT041 CAR T cell therapy for Claudin18.2-positive metastatic pancreatic cancer.

2023-09-0949 citations

Abstract 6482: CLDN18.2 expression is associated with clinicopathological features and prognosis of Chinese patients with digestive system cancers: a retrospective analysis

Cancer Research2023-04-041 citations

Multicenter phase Ib trial in the U.S. of salvage CT041 CLDN18.2-specific chimeric antigen receptor T-cell therapy for patients with advanced gastric and pancreatic adenocarcinoma.

Journal of Clinical Oncology2022-06-0129 citations

Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results.

2022-05-09419 citations